-
★
EU-Arzneimittelbehörde lässt erstes Coronamedikament in Tablettenform zu
(Hinzugefügt: 19.11.2021 um 20:55 Uhr)
https://www.aerzteblatt.de/nachrichten/129273/EU-Arzneimittelbehoerde-laesst-erstes-Coronamedikament-in-Tablettenform-zu
-
★
First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA
(Hinzugefügt: 04.11.2021 um 18:38 Uhr)
https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra
-
★
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
(Hinzugefügt: 11.03.2021 um 08:36 Uhr)
https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/
-
Antiviral activity of molnupiravir precursor NHC against Variants of Concern (VOCs) and its therapeutic window in a human lung cell model
(Hinzugefügt: 25.11.2021 um 12:24 Uhr)
https://www.biorxiv.org/content/10.1101/2021.11.23.469695v1
-
EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19
(Hinzugefügt: 20.11.2021 um 11:07 Uhr)
https://www.ema.europa.eu/en/news/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19
-
Schutz vor schweren Verläufen EMA unterstützt Einsatz von Corona-Pille für Notfälle
(Hinzugefügt: 20.11.2021 um 11:06 Uhr)
https://www.n-tv.de/panorama/EMA-unterstuetzt-Einsatz-von-Corona-Pille-fuer-Notfaelle-article22943162.html
-
Großbritannien lässt Molnupiravir zur Behandlung von COVID-19 zu
(Hinzugefügt: 06.11.2021 um 09:33 Uhr)
https://www.aerzteblatt.de/nachrichten/128810/Grossbritannien-laesst-Molnupiravir-zur-Behandlung-von-COVID-19-zu
-
First pill to treat Covid gets approval in UK
(Hinzugefügt: 04.11.2021 um 18:41 Uhr)
https://www.bbc.com/news/health-59163899
-
Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
(Hinzugefügt: 04.11.2021 um 18:39 Uhr)
https://pubs.acs.org/doi/10.1021/acscentsci.1c00608
-
Estimated cost-based generic prices for molnupiravir for the treatment of COVID-19 infection
(Hinzugefügt: 04.11.2021 um 18:38 Uhr)
https://scholar.harvard.edu/melissabarber/publications/estimated-cost-based-generic-prices-molnupiravir-treatment-covid-19
-
COVID-19: Europäische Arzneimittelagentur prüft Zulassung von Molnupiravir
(Hinzugefügt: 26.10.2021 um 09:04 Uhr)
https://www.aerzteblatt.de/nachrichten/128456/COVID-19-Europaeische-Arzneimittelagentur-prueft-Zulassung-von-Molnupiravir
-
Molnupiravir Mutations
(Hinzugefügt: 18.10.2021 um 10:25 Uhr)
https://www.science.org/content/blog-post/molnupiravir-mutations
-
FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment
(Hinzugefügt: 18.10.2021 um 09:45 Uhr)
https://www.fda.gov/news-events/press-announcements/fda-hold-advisory-committee-meeting-discuss-merck-and-ridgebacks-eua-application-covid-19-oral
-
β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
(Hinzugefügt: 18.10.2021 um 09:41 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136050/
-
How antiviral pill molnupiravir shot ahead in the COVID drug hunt
(Hinzugefügt: 18.10.2021 um 09:40 Uhr)
https://www.nature.com/articles/d41586-021-02783-1
-
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
(Hinzugefügt: 12.10.2021 um 10:36 Uhr)
https://www.merck.com/news/merck-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-u-s-fda-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-c/
-
Tablette gegen Corona: Wie das Medikament Molnupiravir wirkt
(Hinzugefügt: 07.10.2021 um 06:46 Uhr)
https://www.br.de/nachrichten/wissen/wie-gut-ist-das-neue-corona-medikament-molnupiravir,Sl378vi
-
COVID-19: Oraler Wirkstoff Molnupiravir halbiert Hospitalisierungs- und Sterberate bei früher ambulanter Therapie
(Hinzugefügt: 03.10.2021 um 08:16 Uhr)
https://www.aerzteblatt.de/nachrichten/127820/COVID-19-Oraler-Wirkstoff-Molnupiravir-halbiert-Hospitalisierungs-und-Sterberate-bei-frueher-ambulanter-Therapie
-
Molnupiravir: Thor's Hammer Delivers
(Hinzugefügt: 02.10.2021 um 18:20 Uhr)
https://www.science.org/content/blog-post/molnupiravir-thor-s-hammer-delivers
-
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
(Hinzugefügt: 02.10.2021 um 18:20 Uhr)
https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
-
Molnupiravir: coding for catastrophe
(Hinzugefügt: 02.10.2021 um 18:09 Uhr)
https://www.nature.com/articles/s41594-021-00657-8
-
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
(Hinzugefügt: 27.09.2021 um 09:59 Uhr)
https://www.sciencedirect.com/science/article/pii/S2352396421003881
-
"Molnupiravir hat Potenzial" Hoffnung auf neues Corona-Medikament
(Hinzugefügt: 24.08.2021 um 16:26 Uhr)
https://www.n-tv.de/wissen/Hoffnung-auf-neues-Corona-Medikament-article22751801.html
-
Wie das potenzielle Coronamedikament Molnupiravir wirkt
(Hinzugefügt: 24.08.2021 um 16:21 Uhr)
https://www.aerzteblatt.de/nachrichten/126486/Wie-das-potenzielle-Coronamedikament-Molnupiravir-wirkt
-
Molnupiravir, an Oral Antiviral Treatment for COVID-19
(Hinzugefügt: 20.06.2021 um 17:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1
-
USA planen milliardenschwere Bestellung von Coronamedikament
(Hinzugefügt: 11.06.2021 um 05:38 Uhr)
https://www.aerzteblatt.de/nachrichten/124567/USA-planen-milliardenschwere-Bestellung-von-Coronamedikament
-
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
(Hinzugefügt: 13.05.2021 um 17:27 Uhr)
https://www.jbc.org/article/S0021-9258(21)00563-9/fulltext
-
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
(Hinzugefügt: 06.05.2021 um 09:27 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.03.21256309v1
-
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
(Hinzugefügt: 16.04.2021 um 12:26 Uhr)
https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-mild-to-moderate-covid-19/
-
Merck’s Little Brown Pill Could Transform the Fight Against Covid
(Hinzugefügt: 26.03.2021 um 20:49 Uhr)
https://www.bloomberg.com/news/features/2021-03-25/merck-mrk-molnupiravir-pill-could-change-the-fight-against-covid
-
Merck has better luck with 2nd COVID-19 drug attempt as it sees a positive in early molnupiravir data
(Hinzugefügt: 18.03.2021 um 21:56 Uhr)
https://www.fiercebiotech.com/biotech/merck-has-better-luck-second-covid-drug-attempt-as-it-sees-a-positive-early-molnupiravir
-
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
(Hinzugefügt: 14.12.2020 um 07:22 Uhr)
https://www.nature.com/articles/s41564-020-00835-2
-
Molnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model
(Hinzugefügt: 11.12.2020 um 22:44 Uhr)
https://www.biorxiv.org/content/10.1101/2020.12.10.419242v1
-
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
(Hinzugefügt: 11.12.2020 um 07:45 Uhr)
https://clinicaltrials.gov/ct2/show/NCT04405739
-
Molnupiravir Wikipedia
(Hinzugefügt: 10.12.2020 um 09:46 Uhr)
https://en.wikipedia.org/wiki/Molnupiravir